Graig Suvannavejh
Stock Analyst at Goldman Sachs
(0.37)
# 3,597
Out of 4,667 analysts
136
Total ratings
40%
Success rate
-34.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AUTL Autolus Therapeutics | Upgrades: Buy | $7 → $7.6 | $2.80 | +171.43% | 1 | Nov 18, 2024 | |
| IMCR Immunocore Holdings | Downgrades: Neutral | $72 → $38 | $32.42 | +17.21% | 7 | Nov 11, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $39 → $38 | $27.49 | +38.23% | 6 | Oct 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $42 → $52 | $32.79 | +58.58% | 15 | Oct 10, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterates: Outperform | $74 | $16.08 | +360.20% | 1 | Sep 20, 2024 | |
| ATHA Athira Pharma | Downgrades: Neutral | $5 → $0.5 | $0.64 | -22.15% | 3 | Sep 19, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $44 → $49 | $45.76 | +7.08% | 6 | Jul 22, 2024 | |
| IDYA IDEAYA Biosciences | Initiates: Outperform | $50 | $25.54 | +95.77% | 1 | Jul 8, 2024 | |
| NMRA Neumora Therapeutics | Initiates: Outperform | $20 | $9.79 | +104.29% | 1 | Jul 8, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $96 → $100 | $85.64 | +16.77% | 9 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $106 | $94.60 | +12.05% | 16 | Jun 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $82 | $72.67 | +12.84% | 6 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $3 | $0.66 | +351.33% | 1 | May 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $7.80 | +105.13% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $5.23 | -42.64% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $30 | $8.96 | +235.01% | 4 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $22 | $6.17 | +256.56% | 4 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $8 | $2.04 | +292.16% | 1 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 | $8.24 | -57.52% | 1 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $10 | $5.60 | +78.57% | 5 | Nov 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $9 | $3.64 | +147.59% | 4 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $0.59 | +580.27% | 8 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $3.05 | +391.80% | 1 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $59.36 | -41.04% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $5.79 | +38.17% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $49.86 | +14.32% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $31.15 | -83.95% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $4.67 | +628.05% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $5.48 | +410.95% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $31.95 | -2.97% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $19 | $0.79 | +2,290.54% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.69 | +181.82% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $10.18 | +253.63% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $25.64 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $0.96 | +3,747.35% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $119.24 | +7.35% | 1 | Sep 14, 2020 |
Autolus Therapeutics
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $2.80
Upside: +171.43%
Immunocore Holdings
Nov 11, 2024
Downgrades: Neutral
Price Target: $72 → $38
Current: $32.42
Upside: +17.21%
Apellis Pharmaceuticals
Oct 24, 2024
Maintains: Neutral
Price Target: $39 → $38
Current: $27.49
Upside: +38.23%
Harmony Biosciences Holdings
Oct 10, 2024
Maintains: Outperform
Price Target: $42 → $52
Current: $32.79
Upside: +58.58%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $16.08
Upside: +360.20%
Athira Pharma
Sep 19, 2024
Downgrades: Neutral
Price Target: $5 → $0.5
Current: $0.64
Upside: -22.15%
Halozyme Therapeutics
Jul 22, 2024
Maintains: Neutral
Price Target: $44 → $49
Current: $45.76
Upside: +7.08%
IDEAYA Biosciences
Jul 8, 2024
Initiates: Outperform
Price Target: $50
Current: $25.54
Upside: +95.77%
Neumora Therapeutics
Jul 8, 2024
Initiates: Outperform
Price Target: $20
Current: $9.79
Upside: +104.29%
Intra-Cellular Therapies
Jun 21, 2024
Maintains: Buy
Price Target: $96 → $100
Current: $85.64
Upside: +16.77%
Jun 12, 2024
Reiterates: Buy
Price Target: $106
Current: $94.60
Upside: +12.05%
Jun 7, 2024
Maintains: Buy
Price Target: $36 → $82
Current: $72.67
Upside: +12.84%
May 17, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $0.66
Upside: +351.33%
May 16, 2024
Maintains: Buy
Price Target: $14 → $16
Current: $7.80
Upside: +105.13%
May 14, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $5.23
Upside: -42.64%
May 7, 2024
Maintains: Buy
Price Target: $39 → $30
Current: $8.96
Upside: +235.01%
Apr 29, 2024
Maintains: Buy
Price Target: $40 → $22
Current: $6.17
Upside: +256.56%
Apr 2, 2024
Maintains: Buy
Price Target: $20 → $8
Current: $2.04
Upside: +292.16%
Mar 27, 2024
Maintains: Neutral
Price Target: $3.5
Current: $8.24
Upside: -57.52%
Nov 27, 2023
Maintains: Buy
Price Target: $17 → $10
Current: $5.60
Upside: +78.57%
Nov 17, 2023
Maintains: Buy
Price Target: $10 → $9
Current: $3.64
Upside: +147.59%
Aug 23, 2023
Reiterates: Neutral
Price Target: $4
Current: $0.59
Upside: +580.27%
Mar 31, 2023
Initiates: Buy
Price Target: $15
Current: $3.05
Upside: +391.80%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $59.36
Upside: -41.04%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $5.79
Upside: +38.17%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $49.86
Upside: +14.32%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $31.15
Upside: -83.95%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $4.67
Upside: +628.05%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $5.48
Upside: +410.95%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $31.95
Upside: -2.97%
Mar 2, 2021
Initiates: Sell
Price Target: $19
Current: $0.79
Upside: +2,290.54%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.69
Upside: +181.82%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $10.18
Upside: +253.63%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $25.64
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $0.96
Upside: +3,747.35%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $119.24
Upside: +7.35%